| All Releases
|
|---|
 |
Cytori Receives Equity Commitment; Investment Fund to Purchase up to 7.15 Million Shares over Next 12 Months
Jun 22, 2009
|
10.4 KB
|
| |
SAN DIEGO, Jun 22, 2009 (BUSINESS WIRE) -- Cytori Therapeutics (NASDAQ:CYTX) entered into an equity agreement with
Seaside 88, LP ('Seaside'). Under the terms of the agreement, Seaside
has committed to purchase up to 7.15 million Cytori common shares, in a
series of closings every two weeks in the amount of 275,000 shares ea...
|
|
|
Cytori to Present at Two Upcoming Investor Conferences
Jun 1, 2009
|
7.5 KB
|
| |
SAN DIEGO, Jun 01, 2009 (BUSINESS WIRE) -- Cytori Therapeutics (NASDAQ:CYTX) will provide a webcast of its
corporate presentation at two upcoming investor conferences. The Company
will present at the Noble Financial Equity Conference on Monday, June 8,
2009 at 8:05 AM EDT and at the Needham Life Sciences Conference on
...
|
|
|
Cytori Reports Publication of Cardiovascular Preclinical Study; Adipose Stem & Regenerative Cells Improve Function in Heart Attack Model
May 28, 2009
|
10.7 KB
|
| |
SAN DIEGO, May 28, 2009 (BUSINESS WIRE) -- Cytori (NASDAQ: CYTX) announced publication of the first preclinical
study to demonstrate adipose-derived stem and regenerative cells (ADRCs)
significantly improved cardiac function after a heart attack. This
preclinical cardiac cell therapy study was reported online ahead of
...
|
|
|
Cytori Completes Enrollment in First Adipose Stem & Regenerative Cell Therapy Trial for Chronic Heart Disease
May 27, 2009
|
10.3 KB
|
| |
SAN DIEGO, May 27, 2009 (BUSINESS WIRE) -- Cytori (NASDAQ:CYTX) completed enrollment in the first study to
investigate adipose derived stem and regenerative cells in chronic heart
disease. The trial, which has been named the PRECISE study, was carried
out at leading cardiology centers in Europe. It specifically enrolled
...
|
|
|
Cytori Reports First Quarter 2009 Financial Results
May 11, 2009
|
16.9 KB
|
| |
SAN DIEGO, May 11, 2009 (BUSINESS WIRE) -- Cytori Therapeutics (NASDAQ:CYTX) reports financial results for the
first quarter ended March 31, 2009. These results highlight the
Company's progress and demonstrate commercial, clinical and strategic
achievements, which year-to-date include:
Continued growth in product ...
|
|
|
Cytori and GE Healthcare Form Partnership to Commercialize StemSource Products in the U.S.
May 8, 2009
|
10.3 KB
|
| |
SAN DIEGO & CHALFONT ST. GILES, England, May 08, 2009 (BUSINESS WIRE) -- Cytori Therapeutics (NASDAQ:CYTX) and GE Healthcare, a unit of General
Electric Company (NYSE:GE), today announce an agreement by which GE
Healthcare will commercialize Cytori's StemSource(R) technology in the
North American stem cell banking and resear...
|
|
|
Cytori Therapeutics to Raise $4.2 Million Through a Private Placement
May 7, 2009
|
8.2 KB
|
| |
SAN DIEGO, May 07, 2009 (BUSINESS WIRE) -- Cytori Therapeutics, Inc. (NASDAQ: CYTX) entered into definitive
agreements to raise approximately $4.2 million through a private
placement with select investors. The transaction was executed
independently without a placement agent.
At closing, Cytori will issue and sell to investo...
|
|
|
Cytori Therapeutics to Webcast First Quarter Financial Results on May 11, 2009
May 4, 2009
|
7.6 KB
|
| |
SAN DIEGO, May 04, 2009 (BUSINESS WIRE) -- Cytori Therapeutics Inc. (NASDAQ: CYTX) will webcast its first quarter
financial results management discussion on Monday, May 11, 2009 at 10:00
AM Eastern Time.
The webcast will be available both live and by replay two hours after
the call on the Company's website (www.cytoritx.com...
|
|
|
Cytori to Host Investor Call with European Physicians on Cell Enhanced Reconstruction
Apr 30, 2009
|
7.8 KB
|
| |
SAN DIEGO, Apr 30, 2009 (BUSINESS WIRE) -- Cytori Therapeutics (NASDAQ:CYTX) is hosting a webcast on Tuesday May 5,
2009 from 1:00 to 2:00 PM Eastern Time to provide investors with an
update on two European physicians' experience with cell enhanced
reconstruction.
Marc H. Hedrick, M.D., president of Cytori Therapeutics, wil...
|
|
|
Cytori Receives U.S. Patent Allowance for Key Commercial Products
Mar 31, 2009
|
8.5 KB
|
| |
SAN DIEGO, Mar 31, 2009 (BUSINESS WIRE) -- Cytori Therapeutics, Inc. (NASDAQ: CYTX) received a Notice of Allowance
from the U.S. Patent and Trademark Office for a patent application that
protects key therapeutic methods for its breast and soft tissue
reconstruction products. This patent will protect Cytori's existing and
...
|
|
|
Cytori to Present at the 16th Annual Future Leaders in the Biotech Industry Conference on April 2, 2009
Mar 25, 2009
|
7.8 KB
|
| |
SAN DIEGO, Mar 25, 2009 (BUSINESS WIRE) -- Cytori Therapeutics, Inc. (NASDAQ:CYTX) will present and provide an
audio webcast of their corporate presentation at BioCentury's 16th
Annual Future Leaders in the Biotech Industry conference at 11:30 AM
(EST) on Thursday, April 2, 2009 in New York.
The audio webcast may be accesse...
|
|
|
Cytori Therapeutics Closes Previously Announced $10 Million Financing
Mar 13, 2009
|
9.3 KB
|
| |
SAN DIEGO, Mar 13, 2009 (BUSINESS WIRE) -- Cytori Therapeutics, Inc. (NASDAQ:CYTX) closed and received net proceeds
from the definitive agreements the Company entered into on March 10,
2009 to raise $10 million, before placement agent fees and offering
expenses. Cytori offered the securities in this transaction pursuant to
...
|
|
|
Cytori Receives Cell Banking Patent for the Celution(R) System
Mar 11, 2009
|
8.6 KB
|
| |
SAN DIEGO, Mar 11, 2009 (BUSINESS WIRE) -- Cytori Therapeutics, Inc. (NASDAQ:CYTX) received U.S. Patent No.
7,501,115 (the '115 patent), which covers methods of cooling and
cryopreserving stem and regenerative cells processed by the Celution(R)
System. This patent provides additional protection for the Company's
cell...
|
|
|
Cytori Therapeutics to Raise $10 Million in Registered Direct Offering
Mar 10, 2009
|
9.7 KB
|
| |
SAN DIEGO, Mar 10, 2009 (BUSINESS WIRE) -- Cytori Therapeutics, Inc. (NASDAQ: CYTX) entered into definitive
agreements to raise $10 million, before placement agent fees and
offering expenses. At closing, Cytori will issue and sell to select
investors 4,771,174 units, with each unit consisting of one share of the
Comp...
|
|
|
Cytori Stem & Regenerative Cell Heart Attack Trial Feasible & Safe
Mar 6, 2009
|
9.8 KB
|
| |
SAN DIEGO, Mar 06, 2009 (BUSINESS WIRE) -- Cytori Therapeutics, Inc. (NASDAQ: CYTX) completed enrollment in its
APOLLO trial to evaluate the safety and feasibility of adipose
tissue-derived stem and regenerative cells, processed with the Company's
Celution(R) System, in the treatment of severe heart attacks. The steering
...
|
|
|
Cytori Reports Year End 2008 Results; Reviews 2008 Progress and 2009 Business Objectives
Mar 6, 2009
|
18.5 KB
|
| |
SAN DIEGO, Mar 06, 2009 (BUSINESS WIRE) -- Cytori Therapeutics, Inc. (NASDAQ: CYTX) reports financial results for
the year ended December 31, 2008, provides a review of its progress in
2008 and outlines 2009 business objectives.
Highlights for 2008 include the following:
Launch of the Celution(R) System into the cosmetic...
|
|
|
Cytori Therapeutics to Webcast 2008 Earnings Conference Call
Mar 3, 2009
|
6.9 KB
|
| |
SAN DIEGO, Mar 03, 2009 (BUSINESS WIRE) -- Cytori Therapeutics, Inc. (NASDAQ: CYTX) will release its 2008 financial
results on Friday, March 6, 2009 prior to market open. The Company will
host a management conference call starting at 10:30 AM (EST) to discuss
the results and provide an update on the business for 2009.
The w...
|
|
|
Cytori Therapeutics Reports Preliminary 2008 Revenues and 2009 Revenue Guidance
Mar 3, 2009
|
10.0 KB
|
| |
SAN DIEGO, Mar 03, 2009 (BUSINESS WIRE) -- Cytori Therapeutics (NASDAQ: CYTX) today reports 2008 preliminary and
unaudited total revenues of $6.9 million. Celution(R) System and
StemSource(R) product sales accounted for $4.5 million of the total. The
Company forecasts 2009 product revenues of at least $10 million. Product
...
|
|
|
Adipose-Derived Stem and Regenerative Cells Prevent Mortality and Reduce Kidney Damage in Preclinical Study
Feb 25, 2009
|
8.9 KB
|
| |
SAN DIEGO, Feb 25, 2009 (BUSINESS WIRE) -- Cytori Therapeutics, Inc. (NASDAQ: CYTX) finds adipose tissue-derived
stem and regenerative cells (ADRCs) significantly reduce mortality and
improve renal function in an acute kidney injury model. The preclinical
results were reported today at the 14th Annual International
C...
|
|
|
Cytori Patent Allowance Expands Celution(R) System Protection for Adipose Stem & Regenerative Cell Processing
Feb 5, 2009
|
8.7 KB
|
| |
SAN DIEGO, Feb 05, 2009 (BUSINESS WIRE) -- Cytori Therapeutics (NASDAQ: CYTX) received a Notice of Allowance from
the United States Patent and Trademark Office on a patent application
which broadens protection of the Company's Celution(R) System. The more
than 40 allowed claims create several new layers of protection related...
|
|
|
